View in EDS HTML Full Text PDF Full Text

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.

Saved in:

Bibliographic Details
Title:	884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.
Authors:	Teichner, Paula¹ (AUTHOR), Cutrell, Amy¹ (AUTHOR), D'Amico, Ronald¹ (AUTHOR), Dorey, David² (AUTHOR), Griffith, Sandy¹ (AUTHOR), Harrington, Conn M¹ (AUTHOR), Huang, Jenny² (AUTHOR), Hudson, Krischan J¹ (AUTHOR), Margolis, David¹ (AUTHOR), Mrus, Joseph¹ (AUTHOR), Polli, Joseph¹ (AUTHOR), Spreen, William¹ (AUTHOR), Williams, Peter³ (AUTHOR), Solingen-Ristea, Rodica Van³ (AUTHOR), Shaefer, Mark S⁴ (AUTHOR)
Source:	Open Forum Infectious Diseases. 2019 Supplement, Vol. 6, pS20-S20. 1p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	23288957
DOI:	10.1093/ofid/ofz359.043